Gulya A J, Sessions R B, Troost T R
Department of Otolaryngology-Head and Neck Surgery, Georgetown University, Washington, DC.
Am J Otol. 1992 Sep;13(5):438-42.
Aspartame is a low-calorie food sweetener recently approved by the FDA for general human consumption. One of us (AJG) treated a patient whose symptoms of episodic vertigo and continuous unsteadiness resolved upon ceasing aspartame intake. A literature review revealed that although dizziness has been associated with aspartame intake, no systematic study of the problem exists. As an initial attempt to ascertain the prevalence of aspartame-related dizziness in an otolaryngologic clinic, we elected to study prospectively all patients entering with the complaint of vertigo by means of a standardized questionnaire. Those patients determined to consume aspartame were further studied in a nonblinded manner to see if aspartame intake could be correlated to symptomatology. A cross-over limb was also attempted, but no patient would participate. This presentation details the case history of the propositus patient and the preliminary results of the currently ongoing prospective study.
阿斯巴甜是一种低热量食品甜味剂,最近已获美国食品药品监督管理局批准可供一般人食用。我们中的一人(AJG)曾治疗过一名患者,该患者间歇性眩晕和持续性不稳的症状在停止摄入阿斯巴甜后得到缓解。文献综述显示,尽管头晕与阿斯巴甜的摄入有关,但尚未有对该问题的系统性研究。作为在耳鼻喉科诊所确定与阿斯巴甜相关头晕患病率的初步尝试,我们选择通过标准化问卷对所有因眩晕前来就诊的患者进行前瞻性研究。那些被确定食用阿斯巴甜的患者以非盲法进行进一步研究,以观察阿斯巴甜的摄入是否与症状学相关。我们还尝试了交叉分组,但没有患者愿意参与。本报告详细介绍了先证者患者的病史以及当前正在进行的前瞻性研究的初步结果。